Program
evobrutinib
Also written as “Evobrutinib”, “M2951” and “MSC2364447C”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid · Autoimmune Diseases, led by Merck KGaA, Darmstadt, Germany.
Drug pageEvobrutinib: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 200 open or running | phase 3since Jul 23, 2019 | Aug 28, 2015 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Aug 28, 2015.
- May 24, 2016Phase 2 study in Arthritis, RheumatoidNCT02784106 · 65 enrolled · United States, Germany
- Jun 9, 2016Named evobrutinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, M2951, MSC2364447C
- Nov 23, 20162 phase 2 studiesNCT02975349, NCT02975336
- Jul 25, 2017Phase 2 study in Arthritis, RheumatoidNCT03233230 · 390 enrolled · United States, Argentina, Bulgaria and more
- Feb 6, 2018Phase 1 study in Renal InsufficiencyNCT03436394 · 31 enrolled · Germany
- Oct 29, 2018Phase 1 study in HealthyNCT03725072 · 6 enrolled · Netherlands
- Apr 29, 2019Phase 1 study in HealthyNCT03934502 · 20 enrolled · Germany
- Jul 23, 20192 phase 3 studies in Multiple Sclerosis, Relapsing-RemittingNCT04032171, NCT04032158
- Mar 17, 2020Phase 1 study in HealthyNCT04314024 · 18 enrolled · Germany
- Apr 6, 20202 phase 3 studies in Relapsing Multiple SclerosisNCT04338061, NCT04338022
- Sep 10, 2020Phase 1 study in Hepatic ImpairmentNCT04546789 · 24 enrolled · Germany
- Jan 4, 2021Phase 1 study in Autoimmune DiseasesNCT04697511 · 16 enrolled · Germany
- Sep 23, 2021Phase 1 study in HealthyNCT05064488 · 40 enrolled · Germany
- Jan 13, 20222 phase 1 studies in HealthyNCT05248945, NCT05245396
- Oct 8, 20252 phase 1 studies in HealthyNCT07214935, NCT07214922
TargetBeta
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07214935Healthy · Germany | 1 | Completed | Aug 25, 2023 | 36 |
| NCT07214922Healthy · Germany | 1 | Completed | Feb 24, 2023 | 28 |
| NCT05245396Healthy · United Kingdom | 1 | Completed | Feb 14, 2023 | 58 |
| NCT05248945Healthy · Germany | 1 | Completed | Jul 18, 2022 | 14 |
| NCT05064488Healthy · Germany | 1 | Completed | Dec 10, 2021 | 40 |
| NCT04697511Autoimmune Diseases · Germany | 1 | Completed | Feb 25, 2021 | 16 |
| NCT04546789Hepatic Impairment · Germany | 1 | Completed | May 16, 2021 | 24 |
| NCT04338061Relapsing Multiple Sclerosis · United States, Belarus, Brazil and more | 3 | Terminated | Oct 2, 2023 | 1,166 |
| NCT04338022Relapsing Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Terminated | Oct 2, 2023 | 1,124 |
| NCT04314024Healthy · Germany | 1 | Completed | Jun 23, 2020 | 18 |
| NCT04032171Multiple Sclerosis, Relapsing-Remitting · United States, Germany | 3 | Terminated | May 20, 2020 | 1 |
| NCT04032158Multiple Sclerosis, Relapsing-Remitting · United States, Germany | 3 | Terminated | Apr 16, 2020 | 3 |
| NCT03934502Healthy · Germany | 1 | Completed | Jun 12, 2019 | 20 |
| NCT03725072Healthy · Netherlands | 1 | Completed | Dec 5, 2018 | 6 |
| NCT03436394Renal Insufficiency · Germany | 1 | Completed | Feb 22, 2019 | 31 |
| NCT03233230Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more | 2 | Completed | Sep 23, 2019 | 390 |
| NCT02975349Multiple Sclerosis, Relapsing-Remitting · Bulgaria, Czechia, Poland and more | 2 | Terminated | Jan 24, 2018 | 267 |
| NCT02975336Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more | 2 | Terminated | Nov 27, 2019 | 469 |
| NCT02784106Arthritis, Rheumatoid · United States, Germany | 2 | Completed | Apr 30, 2017 | 65 |
| NCT02537028Lupus Erythematosus, Systemic · United States, Bulgaria | 1 | Completed | Oct 4, 2016 | 24 |
How it is read
Names in the registry
- “Evobrutinib”, 12 entries
- “M2951”, 7 entries
- “MSC2364447C”, 2 entries
- “Treatment A”, 1 entry
- “Treatment B”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 3 studies
- Multiple Sclerosis, 2 studies
- Lupus Erythematosus, Systemic, 2 studies
- Arthritis, Rheumatoid, 2 studies
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.